Skinvisible (SKVI) Cash & Equivalents Growth (1y) (2012 - 2026)
Powered by 
Analysis
Skinvisible (SKVI) Cash & Equivalents Growth (1y) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 9.93% |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | 1.58% |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | -14.46% |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | 14.42% |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | -40.42% |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | -57.55% |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | 103.71% |
| 9 | United Therapeutics | 20.81 Bn | 18.15 Bn | 683.80 Mn | 13.19% |
| 10 | Skinvisible | 1.08 Mn | 1.08 Mn | 5,000.00 | 3,199.17% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3,199.17% |
| Mar 31, 2026 | -86.58% |
| Dec 31, 2025 | -74.65% |
| Sep 30, 2025 | 5.39% |
| Jun 30, 2025 | -98.28% |
| Mar 31, 2025 | 65.44% |
| Dec 31, 2024 | 1,063.96% |
| Sep 30, 2024 | -16.28% |
| Jun 30, 2024 | 97.01% |
| Mar 31, 2024 | -72.21% |
| Dec 31, 2023 | -98.91% |
| Sep 30, 2023 | -99.43% |
| Jun 30, 2023 | -97.79% |
| Mar 31, 2023 | 16.10% |
| Dec 31, 2022 | 23.23% |
| Sep 30, 2022 | 158.85% |
| Jun 30, 2022 | 191.65% |
| Mar 31, 2022 | 98.13% |
| Dec 31, 2021 | 83.97% |
| Sep 30, 2021 | 316.47% |